CMW Media client AXIM Biotechnologies was featured in an article on Benzinga discussing their receiving of a Notice of Allowance for a patent application that they filed for their topical eczema cream.

“Axim said it expects that its topical cream will be one of the first CBG products available on the market — and it won’t require a prescription. With this product, AXIM expects to enter an atopic dermatitis market that is valued at $5 billion.”

Read the FULL ARTICLE HERE